Cargando…

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

Chronic hepatitis B (CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue (NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B virus (HBV) infection. The accepted endpoint for therapy is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreno-Cubero, Elia, del Arco, Robert T Sánchez, Peña-Asensio, Julia, de Villalobos, Eduardo Sanz, Míquel, Joaquín, Larrubia, Juan Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937201/ https://www.ncbi.nlm.nih.gov/pubmed/29740199 http://dx.doi.org/10.3748/wjg.v24.i17.1825

Ejemplares similares

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history
por: Peña-Asensio, Julia, et al.
Publicado: (2020)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
por: Hall, Samuel, et al.
Publicado: (2020)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8(+) T Cell Response during Chronic Hepatitis C
por: Peña-Asensio, Julia, et al.
Publicado: (2021)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
por: de Fraga, Raquel Scherer, et al.
Publicado: (2020)

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
por: Roade, Luisa, et al.
Publicado: (2021)

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes
por: Van Hees, S., et al.
Publicado: (2018)

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8(+) T Cell Response in Hepatocellular Carcinoma
por: Peña-Asensio, Julia, et al.
Publicado: (2021)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
por: Papatheodoridi, Margarita, et al.
Publicado: (2020)

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020)

Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
por: Broquetas, Teresa, et al.
Publicado: (2022)

Model to predict on‐treatment restoration of functional HBV‐specific CD8 (+) cell response foresees off‐treatment HBV control in eAg‐negative chronic hepatitis B
por: Peña‐Asensio, Julia, et al.
Publicado: (2022)

Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B
por: Xie, Linqing, et al.
Publicado: (2019)

Differential response of HBV envelope-specific CD4(+) T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy
por: Li, Yongyin, et al.
Publicado: (2023)

Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis
por: Chen, Zhe, et al.
Publicado: (2015)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?
por: Adali, Gupse, et al.
Publicado: (2021)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
por: Hsu, Yao-Chun, et al.
Publicado: (2023)

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
por: Gao, Yu-Hua, et al.
Publicado: (2016)

Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing
por: Nishijima, Norihiro, et al.
Publicado: (2012)

Impact of Nucleos(t)ide Analogue Combination Therapy on the Estimated Glomerular Filtration Rate in Patients With Chronic Hepatitis B
por: Qi, Xun, et al.
Publicado: (2015)

Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B
por: Sun, Y., et al.
Publicado: (2019)

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis
por: Ford, Nathan, et al.
Publicado: (2018)

TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
por: Huang, Mingxing, et al.
Publicado: (2017)

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B
por: Zhou, Jialing, et al.
Publicado: (2016)

Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B
por: Madeddu, Giordano, et al.
Publicado: (2020)

Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation
por: Lai, Chia-Yeh, et al.
Publicado: (2021)

Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta‐analysis
por: Lai, Quirino, et al.
Publicado: (2021)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
por: Scheller, Laura, et al.
Publicado: (2021)

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
por: He, Dengming, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_avfe8majkkjjrbggarkm4fvv1r